1Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/fotinic acid plus oxaliplalin as first-line therapy for metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26 (12) : 2006- 2012.
2Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinoteean plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study[J]. J Clin Oncol, 2007,25 (30) : 4779-4786.
3Porsehen R, Arkenau HT, Kubicka S, et al. Phase Ⅲ study of eapeeitabine plus oxaliplatin compared with fluorouraeil and leueovorin plus oxaliplatin in metastatic eoloreetal cancer: a final report of the AIO Cotoreeud Study Group[J]. J Clin Oncol, 2007,25(27):4217-4223.
4Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised muticentre phase Ⅲ study comparing eapecitabine with fluorouraeil and oxaliplatin with cisplatin in patients with advanced oesoph-agogastric cancer receiving ECF[J]. Br J Cancer, 2005,92 ( 11 ) : 1976-1983.
8Takahashi Y,Takeuehi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study[J]. Gastric Cancer, 2003,6(3): 142-145.
3Park YH, Lee JL, Ryoo BY, et al. Capeeitabine in combina tion with Oxaliplatin (XELOX) as a first-line therapy for ad vanced gastric cancer [J] Cancer Chemother Pharmacol 2008, 61 (4) :623-629.
4Park YH, Kim BS, Ryoo BY, et al. A phase Ⅱ study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer[J]. Br J Cancer, 2006, 94(7):959-963.
5Zaniboni A, Meriqqi F. The emerging role of oxaliplatin in the treatment of gastric cancer[J]. J Chemother, 2005, 17 (6) : 656-662.
6Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of eapecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26 (12):2006-2012.
7Porschen R, Arkenau HT, Kubicka S, et al. Phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group[J]. J Clin Oncol, 2007, 25(27) :4217-4223.
8Sumpter K, Harper - Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF [J]. Br J Cancer, 2005, 92 (11 ):1976-1983.
9张学庸.胃癌的基础研究与临床[M].北京:科学出版社,1999.61.
10Mitsugu K,Masashi F,Noriaki K,et al.Evaluation of serum CEA and CA199 levels as prognostic factors in patients with gastric cancer[J].Gastric Cancer,2000,3(4):177-186.
